KR20190085565A - Composition for fatigue recovery comprising Pinus koraiensis leaves extract as effective component - Google Patents
Composition for fatigue recovery comprising Pinus koraiensis leaves extract as effective component Download PDFInfo
- Publication number
- KR20190085565A KR20190085565A KR1020170168909A KR20170168909A KR20190085565A KR 20190085565 A KR20190085565 A KR 20190085565A KR 1020170168909 A KR1020170168909 A KR 1020170168909A KR 20170168909 A KR20170168909 A KR 20170168909A KR 20190085565 A KR20190085565 A KR 20190085565A
- Authority
- KR
- South Korea
- Prior art keywords
- fatigue
- extract
- composition
- blood
- functional food
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 238000011084 recovery Methods 0.000 title claims abstract description 6
- 240000007263 Pinus koraiensis Species 0.000 title abstract description 7
- 235000011615 Pinus koraiensis Nutrition 0.000 title abstract description 6
- 235000013376 functional food Nutrition 0.000 claims abstract description 19
- 230000036541 health Effects 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 206010049565 Muscle fatigue Diseases 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- -1 ring Substances 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 240000009188 Phyllostachys vivax Species 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000021466 carotenoid Nutrition 0.000 claims description 2
- 150000001747 carotenoids Chemical class 0.000 claims description 2
- 239000006046 creatine Substances 0.000 claims description 2
- 229960003624 creatine Drugs 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 235000004347 Perilla Nutrition 0.000 claims 1
- 244000124853 Perilla frutescens Species 0.000 claims 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract description 34
- 230000009182 swimming Effects 0.000 abstract description 23
- 229960000890 hydrocortisone Drugs 0.000 abstract description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract description 7
- 210000002966 serum Anatomy 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 4
- 206010016256 fatigue Diseases 0.000 description 42
- 210000004369 blood Anatomy 0.000 description 35
- 239000008280 blood Substances 0.000 description 35
- 241000018646 Pinus brutia Species 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 26
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 26
- 235000011613 Pinus brutia Nutrition 0.000 description 26
- 230000000694 effects Effects 0.000 description 23
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 20
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 15
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- 229910021529 ammonia Inorganic materials 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 239000013642 negative control Substances 0.000 description 6
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 5
- 238000004737 colorimetric analysis Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 235000010724 Wisteria floribunda Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101150004094 PRO2 gene Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 241000238565 lobster Species 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- JYGXADMDTFJGBT-MKIDGPAKSA-N 11alpha-Hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-MKIDGPAKSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000238553 Litopenaeus vannamei Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241000164535 Pantoea intestinalis Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 235000000405 Pinus densiflora Nutrition 0.000 description 1
- 240000008670 Pinus densiflora Species 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 206010040021 Sensory abnormalities Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000004121 glycogenesis Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
Abstract
Description
본 발명은 잣나무 잎 추출물을 유효성분으로 포함하는 피로 회복용 조성물에 관한 것이다.The present invention relates to a composition for restoring fatigue comprising an extract of pine tree leaf as an active ingredient.
피로는 일반적으로 일상적인 활동 이후의 비정상적인 탈진 증상, 기운이 없어서 지속적인 노력이나 집중이 필요한 일을 할 수 없는 상태, 일상적인 활동을 수행할 수 없을 정도로 전반적으로 기운이 없는 상태로 정의하는데, 이러한 피로가 1개월 이상 계속되는 경우는 지속성(prolonged) 피로라고 부르고, 6개월 이상 지속되는 경우를 만성(chronic) 피로라고 부른다. Fatigue is generally defined as a state of abnormal burning after routine activities, a state in which there is no aura and can not perform a continuous effort or concentration, or a general lack of energy to perform routine activities. Is called prolonged fatigue if it lasts more than one month, and chronic fatigue if it lasts longer than six months.
만성 피로 증후군은 잠깐의 휴식으로 회복되는 일과성 피로와 달리, 휴식을 취해도 호전되지 않으면서 환자를 매우 쇠약하게 만드는 피로가 지속된다. 만성 피로 증후군의 원인에 대해서는 아직까지 확실하게 밝혀진 것이 없다. 다만 관련 질환으로 바이러스 감염을 포함한 각종 감염증, 일과성 외상 혹은 충격, 극심한 스트레스, 독성 물질 등이 거론되고 있다. 최근에는 중추신경계의 장애에 의한 질환이라는 주장이 제기되고 있는데, 그 근거로는 만성 피로 증후군 환자들에게서 집중력 장애, 주의력 장애, 기억력 장애, 감각 이상 같은 증상들이 빈발한다는 점과, 그 중 5~15%의 환자들에게서 발병 후 첫 6개월 이내에 일시적인 마비, 시각장애, 운동부조화, 혹은 혼란(confusion) 등과 같은 증상이 나타난다는 점을 들 수 있다. 이러한 증상들은 중추신경계에 이상이 생겼을 때 나타나기 때문에, 만성 피로 증후군과 중추신경계의 연관성을 시사해준다. 또한 만성 피로 증후군 환자들에서 뇌 혈류가 감소되는 사례가 SPECT 검사에서 발견되거나, 각종 신경전달 물질들의 이상 소견이 발견된다는 학설도 제기되고 있지만 아직까지 명쾌한 원인은 밝혀지지 않은 상태다.Chronic Fatigue Syndrome, unlike transient fatigue that recovers from a short break, continues to cause fatigue, which makes the patient very debilitated without taking a rest. The cause of chronic fatigue syndrome has yet to be clarified. However, related diseases include various infectious diseases including virus infection, transient trauma or shock, extreme stress, and toxic substances. Recently, it has been argued that the disorder is caused by central nervous system disorder. The reason is that the symptoms such as concentration disorder, attention disorder, memory disorder, and sensory abnormality occur frequently in patients with chronic fatigue syndrome, % Of patients present with symptoms such as temporary paralysis, visual impairment, mismatching, or confusion within the first 6 months after the onset of the disease. Since these symptoms occur when an abnormality occurs in the central nervous system, it suggests a link between the chronic fatigue syndrome and the central nervous system. In addition, patients with chronic fatigue syndrome who have decreased cerebral blood flow is found in the SPECT test, or abnormal findings of various neurotransmitters have been found that the theory has been raised, but the cause is not yet clear.
한편, 잣나무는 주요한 산림자원으로 여겨지고 있으나, 열매인 잣과 목재 이외에는 별도로 활용되지 못하고 있다. 특히, 잣잎은 잎 표면의 왁스 층이 두터울 뿐만 아니라, 떫은 맛이 강하여 거의 활용되지 않고 있는 실정이다. 잣잎은 한방에서는 백엽(柏葉)이라 하는데, 0.25~0.41%의 정유, 350mg%의 플라보노이드, 260~360mg%의 아스코르빈산이 함유되어 있어, 소화기를 강화시켜 준다고 알려져 있다. 민간요법으로는 싱싱한 잣잎을 골라 물로 세척한 다음, 수분을 제거하고, 이를 차관에 넣고 물을 부어 은근하게 끓인 백엽차를 어린이의 설사 및 이질의 치료에 사용하여 왔다. 이처럼 민간요법으로 사용되는 백엽차의 기호성을 증진시키기 위하여, 잣잎과 설탕을 용해시킨 액을 항아리에 첨가하여 서늘한 장소에서 숙성시켜 수득한 당액을 물로 희석하여 사용하기도 하였다. On the other hand, pine wood is considered as a major forest resource, but it is not utilized separately except for the nut of pine and wood. Especially, the shingled leaf has not only a wax layer on the surface of the leaves but also a strong taste. The shingles are called "柏葉" in the oriental medicine. It contains 0.25 ~ 0.41% essential oil, 350mg% flavonoid, 260 ~ 360mg% ascorbic acid, which is known to strengthen the digestive system. In the case of folk remedies, fresh shrimp leaves were washed with water, then water was removed, the leaves were poured in water, and a lobster tea boiled in water was used to treat diarrhea and dysentery in children. In order to improve the palatability of the lobster tea used as the folk remedy, the liquid obtained by dissolving the sham-leaf and the sugar in the jar was aged in a cool place and diluted with water was used.
잣나무 잎 추출물 관련 선행 기술로는 한국공개특허 제2012-0012639호에 잣나무 추출물을 함유하는 음료 및 그 제조방법이 개시되어 있고, 한국공개특허 제2011-0056053호에 항산화 기능을 구비한 잣잎 추출물의 분리방법 및 그 추출물이 개시되어 있으나, 본 발명의 잣나무 잎 추출물을 유효성분으로 포함하는 피로 회복용 조성물에 대해서 개시된 바는 없다.Prior art related to the pine leaf extract has been disclosed in Korean Patent Publication No. 2012-0012639, a beverage containing a pine tree extract and a preparation method thereof, and Korean Patent Publication No. 2011-0056053 discloses separation And an extract thereof are disclosed, but no fatigue recovery composition containing the extract of Pine Pinaceae of the present invention as an active ingredient has been disclosed.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명은 잣나무(Pinus koraiensis Siebold & Zucc.) 잎 추출물을 유효성분으로 포함하는 피로 회복용 조성물을 제공하고, 강제수영운동에 의해 스트레스 및 피로가 유발된 ICR 생쥐에서 잣나무 잎 추출물을 투여하였을 때, 스트레스 및 피로에 의한 활동성 감소를 개선하는 효과를 확인하였으며, 혈액 내 젖산(Lactate), 암모니아(NH3), 혈액요소질소(BUN), 젖산탈수화효소(LDH) 및 코르티졸(Cortisol) 함량이 감소한 것을 확인함으로써, 본 발명을 완성하였다. The present invention is derived by the request as described above, the present invention is pine (Pinus The present invention provides a composition for restoring fatigue comprising leaf extract as an active ingredient and is useful as an active ingredient for the stress and fatigue induced ICR mice, (NH 3 ), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and cortisol content in the blood were decreased. As a result, the present invention .
상기 목적을 달성하기 위하여, 본 발명은 잣나무 잎 추출물을 유효성분으로 포함하는 피로 회복용 건강기능식품 조성물을 제공한다.In order to achieve the above object, the present invention provides a health functional food composition for restoring fatigue comprising an extract of P. vivax as an active ingredient.
또한, 본 발명은 상기 조성물을 인간이 아닌 개체에게 투여하는 단계를 포함하는, 피로를 회복하는 방법을 제공한다.The present invention also provides a method of restoring fatigue comprising the step of administering the composition to a non-human subject.
본 발명은 잣나무 잎 추출물을 유효성분으로 포함하는 피로 회복용 조성물에 관한 것으로, 젖산(Lactate), 암모니아(NH3), 혈액요소질소(BUN), 젖산탈수화효소(LDH) 및 코르티졸(Cortisol)의 함량을 감소시킬 뿐만 아니라, 강제수영 동물 모델에서 스트레스 및 피로에 의한 활동성 감소를 개선하는 효과가 있다. The present invention relates to a composition for restoring fatigue comprising an extract of Pine Pinus densiflora as an active ingredient, which comprises lactate, ammonia (NH 3 ), blood urea nitrogen (BUN), lactate dehydrogenase (LDH) and cortisol , As well as the effect of reducing stress and fatigue activity in forced swimming animal models.
도 1은 강제수영운동으로 스트레스 및 피로가 유발된 ICR 생쥐(Vehicle)에서 잣나무 잎 추출물 100mg/kg(PKE-100), 잣나무 잎 추출물 200mg/kg(PKE-200) 및 홍경천 추출물(PC) 100mg/kg을 10일 동안 투여하고, 1, 5, 10일째 체중을 측정한 결과를 나타낸 것이다(#: p<0.05 vs. vehicle).
도 2는 강제수영운동으로 스트레스 및 피로가 유발된 ICR 생쥐(Vehicle)에서 잣나무 잎 추출물 100mg/kg(PKE-100) 및 홍경천 추출물(PC) 100mg/kg을 10일 동안 투여하고, 중량부하 강제수영 검사를 실시한 결과로, 수중에서의 수영지속 시간을 나타낸 것이다(##: p<0.01, ###: p<0.001 vs. vehicle).
도 3은 강제수영운동으로 스트레스 및 피로가 유발된 ICR 생쥐(Vehicle)에서 잣나무 잎 추출물 100mg/kg(PKE-100), 잣나무 잎 추출물 200mg/kg(PKE-200) 및 홍경천 추출물(PC) 100mg/kg을 10일 동안 투여하고, 11일째 얻은 혈액에서 젖산(Lactate)의 농도를 젖산 산화효소 전극 방법으로 측정한 결과를 나타낸 것이다(#: p<0.05, ##: p<0.01, ####: p<0.0001 vs. vehicle).
도 4는 강제수영운동으로 스트레스 및 피로가 유발된 ICR 생쥐(Vehicle)에서 잣나무 잎 추출물 100mg/kg(PKE-100), 잣나무 잎 추출물 200mg/kg(PKE-200) 및 홍경천 추출물(PC) 100mg/kg을 10일 동안 투여하고, 11일째 얻은 혈액에서 암모니아(Ammonia)의 농도를 비색법으로 측정한 결과를 나타낸 것이다(####: p<0.0001 vs. vehicle).
도 5는 강제수영운동으로 스트레스 및 피로가 유발된 ICR 생쥐(Vehicle)에서 잣나무 잎 추출물 100mg/kg(PKE-100), 잣나무 잎 추출물 200mg/kg(PKE-200) 및 홍경천 추출물(PC) 100mg/kg을 10일 동안 투여하고, 11일째 얻은 혈액에서 혈액요소질소(Blood urea nitrogen, BUN)의 농도를 비색법으로 측정한 결과를 나타낸 것이다(#: p<0.05 vs. vehicle).
도 6은 강제수영운동으로 스트레스 및 피로가 유발된 ICR 생쥐(Vehicle)에서 잣나무 잎 추출물 100mg/kg(PKE-100), 잣나무 잎 추출물 200mg/kg(PKE-200) 및 홍경천 추출물(PC) 100mg/kg을 10일 동안 투여하고, 11일째 얻은 혈액에서 젖산탈수화효소(Lactate dehydrogenase, LDH)의 농도를 비색법으로 측정한 결과를 나타낸 것이다(###: p<0.001 vs. vehicle).
도 7은 강제수영운동으로 스트레스 및 피로가 유발된 ICR 생쥐(Vehicle)에서 잣나무 잎 추출물 100mg/kg(PKE-100), 잣나무 잎 추출물 200mg/kg(PKE-200) 및 홍경천 추출물(PC) 100mg/kg을 10일 동안 투여하고, 11일째 얻은 혈액에서 코르티졸(Cortisol)의 농도를 효소면역 측정법으로 확인한 결과를 나타낸 것이다(#: p<0.05 vs. vehicle). Fig. 1 shows that 100 mg / kg (PKE-100), pine
Fig. 2 shows the results of a 10-day administration of 100 mg / kg of pine tree leaf extract (100 mg / kg) (PKE-100) As a result of the test, it shows the swimming duration in water (##: p <0.01, ###: p <0.001 vs. vehicle).
FIG. 3 is a graph showing the results of stress and fatigue induced ICR mice induced by forced swimming in 100 mg / kg (PKE-100), 200 mg / kg (PKE-200) kg for 10 days and the concentration of lactate in the blood obtained on day 11 was measured by lactic acid oxidase electrode method (#: p <0.05, ##: p <0.01, #### : p < 0.0001 vs. vehicle).
FIG. 4 shows the results of stress and fatigue-induced ICR mice induced by forced swimming in 100 mg / kg (PKE-100), 100 mg / kg (PKE-200) kg for 10 days, and the concentration of ammonia (Ammonia) in the blood obtained on the 11th day was colorimetrically measured (####: p <0.0001 vs. vehicle).
FIG. 5 shows the results of stress and fatigue induced ICR mice induced by swimming with 100 mg / kg (PKE-100),
FIG. 6 shows the results of stress and fatigue induced ICR mice induced by forced swimming in 100 mg / kg (PKE-100), 100 mg / kg (PKE-200) kg for 10 days, and the concentration of lactate dehydrogenase (LDH) in the blood obtained on day 11 was measured by colorimetry (###: p <0.001 vs. vehicle).
Figure 7 shows the results of stress and fatigue-induced ICR mice induced by forced swimming in 100 mg / kg (PKE-100),
본 발명은 잣나무 잎 추출물을 유효성분으로 포함하는 피로 회복용 건강기능식품 조성물에 관한 것이다.The present invention relates to a health functional food composition for restoring fatigue comprising a pine cone leaf extract as an active ingredient.
상기 잣나무 잎 추출물은 하기의 단계를 포함하는 방법에 의해 제조할 수 있으나, 이에 한정하지 않는다:The Pine leaf blade extract may be prepared by a method including, but not limited to, the following steps:
(1) 잣나무 잎 건조 분말에 추출용매를 가하여 추출하는 단계;(1) extracting a dry powder of pine tree by adding an extraction solvent;
(2) 단계 (1)의 추출물을 여과하는 단계; 및 (2) filtering the extract of step (1); And
(3) 단계 (2)의 여과한 추출물을 감압 농축하고 건조하여 추출물을 제조하는 단계. (3) The step of extracting the filtered extract of step (2) by concentration under reduced pressure and drying.
상기 단계 (1)에서 추출용매는 물, C1~C4의 저급 알코올 또는 이들의 혼합물 중에서 선택하는 것이 바람직하며, 더 바람직하게는 에탄올이고, 더욱더 바람직하게는 80%(v/v) 에탄올이지만 이에 한정하지 않는다.In the step (1), the extraction solvent is preferably selected from water, a C 1 -C 4 lower alcohol or a mixture thereof, more preferably ethanol, even more preferably 80% (v / v) ethanol But is not limited thereto.
상기 제조방법에 있어서, 추출방법은 여과법, 열수 추출, 침지 추출, 환류 냉각 추출 및 초음파 추출 등의 당 업계에 공지된 모든 통상적인 방법을 이용할 수 있다. 상기 추출용매는 건조된 잣나무 잎 중량의 1~20배 첨가하여 추출하는 것이 바람직하며, 더 바람직하게는 5~15배 첨가하는 것이다. 추출온도는 4~100℃인 것이 바람직하지만 이에 한정하지 않는다. 또한, 추출시간은 0.5~10시간인 것이 바람직하며, 0.5~6시간이 더욱 바람직하고, 4시간이 가장 바람직하나 이에 한정하지 않는다. 상기 방법에 있어서, 단계 (3)의 감압농축은 진공 감압 농축기 또는 진공회전증발기를 이용하는 것이 바람직하나 이에 한정하지 않는다. 또한, 건조는 감압건조, 진공건조, 비등건조, 분무 건조 또는 동결 건조하는 것이 바람직하나 이에 한정하지 않는다.In the above production method, any conventional method known in the art such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction may be used. The extraction solvent is preferably added by 1 to 20 times the weight of the dried pine tree leaves, more preferably 5 to 15 times. The extraction temperature is preferably 4 to 100 DEG C, but is not limited thereto. The extraction time is preferably 0.5 to 10 hours, more preferably 0.5 to 6 hours, most preferably 4 hours, but not always limited thereto. In the above method, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in the step (3), but it is not limited thereto. The drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto.
상기 피로는 운동에 의한 근육 피로 또는 스트레스에 의해 유발된 피로인 것을 특징으로 하며, 근육 피로는 피로감, 지구력 저하, 순발력 저하 또는 무기력 증세로 나타날 수 있다. The fatigue is characterized by being fatigue caused by muscle fatigue or stress caused by exercise, and muscle fatigue may be caused by fatigue, decreased endurance, impaired ability to work, or lethargy.
본 발명의 일 구현 예에 따른 피로 회복용 건강기능식품 조성물은 상기 유효성분 이외에 타우린, 크레아틴, 비타민E, 비타민C, 카로티노이드, 환원형 글루타티온 및 미네랄류 중에서 선택된 1종 이상을 더 포함할 수 있다. The health functional food composition for fatigue recovery according to an embodiment of the present invention may further include at least one selected from the group consisting of taurine, creatine, vitamin E, vitamin C, carotenoid, reduced glutathione, and minerals in addition to the active ingredient.
상기 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나의 제형으로 제조되는 것이 바람직하나 이에 한정하는 것은 아니다. The composition is preferably prepared by any one of powder, granule, ring, tablet, capsule, candy, syrup and beverage, but is not limited thereto.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다.When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is, or may be used together with other food or food ingredients, and suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably used depending on the purpose of use (prevention or improvement). Generally, the health functional food composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight based on the raw material, when the food or beverage is produced. However, in the case of long-term intake intended for health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount of more than the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 수프, 음료수, 차 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the health functional food. Examples of foods to which the health functional food composition can be added include meat products, sausages, breads, chocolate, candies, snacks, confectionery, pizza, ramen noodles, other noodles, gums, dairy products including ice cream, various soups, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.
또한, 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함할 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로오스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등), 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다.In addition, the health functional food composition of the present invention can be produced as a food, particularly a functional food. The functional food of the present invention includes components that are ordinarily added in food production, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, when it is made of a drink, it may contain, in addition to the active ingredient, a natural carbohydrate or a flavoring agent as an additional ingredient. The natural carbohydrate may be selected from the group consisting of monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g., dextrin, cyclodextrin, For example, xylitol, sorbitol, erythritol, etc.). The flavoring agent may be a natural flavoring agent (e.g., tau Martin, stevia extract, etc.) and a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. 이러한 상기 첨가되는 성분의 비율은 크게 중요하진 않지만 본 발명의 건강기능식품 조성물 100 중량부에 대하여, 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above health functional food composition, it is also possible to use various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, A carbonating agent used in beverages, and the like. Although the ratio of the above-mentioned ingredients is not critical, it is generally selected in the range of 0.01 to 0.1 part by weight based on 100 parts by weight of the health functional food composition of the present invention.
또한, 본 발명에 따른 조성물을 인간이 아닌 개체에게 투여하는 단계를 포함하는, 피로를 회복하는 방법에 관한 것이다.The invention also relates to a method of restoring fatigue comprising the step of administering a composition according to the invention to a non-human subject.
이하, 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.
1. 실험재료1. Experimental material
양성대조군(PC)으로 사용된 홍경천 추출물(Rhodiola rosea extract)은 ㈜SK바이오랜드에서 제공받아 사용하였으며, CMC(Carboxymethylcellulose sodium)는 시그마(Sigma, St. Louis, MO USA)로부터 구입하여 사용하였다. The honggyeongcheon extract (Rhodiola used as a positive control (PC) rosea extract was purchased from SK Bioland, and CMC (carboxymethylcellulose sodium) was purchased from Sigma (St. Louis, Mo. USA).
2. 추출물의 제조2. Preparation of extract
잣나무(Pinus koraiensis) 잎 무게의 10배에 해당하는 80%(v/v) 에탄올을 넣고, 70℃에서 4시간 동안 환류추출 하였다. 추출 후, 여과지를 이용하여 걸러내고, 증류장치를 이용하여 감압 농축하고, 동결건조한 후, 클로로필을 제거하여 잣나무 잎 추출물(PKE)을 제조하였다. Pinus pinus koraiensis) into a 80% (v / v) ethanol, corresponding to 10 times the leaf weight, and extracted under reflux at 70 ℃ for 4 hours. After extraction, the mixture was filtered using a filter paper, concentrated under reduced pressure using a distillation apparatus, lyophilized, and then chlorophyll removed to prepare a pine needle leaf extract (PKE).
3. 스트레스 부가 강제수영운동(Weight-Loaded Forced Swim)에 의한 피로유발 3. Fatigue induced by stress-induced weight-loaded forced swim
수컷 5주령의 ICR 생쥐는 ㈜대한바이오링크(Chungbuk, Korea)에서 공급받았고, 동물은 실험 당일까지 고형사료(항생제 무첨가, 삼양사료 Co.)와 물을 충분히 공급하고, 온도 22±2℃, 습도 55±15%, 12시간 명암주기의 환경을 유지하며 1주 동안 적응시킨 후 실험에 사용하였다. 스트레스 및 피로를 유발하기 위하여 체중의 5%에 해당하는 무게 추를 생쥐 꼬리에 부착하고 시험일 전까지 격일로 1회 30분 동안, 총 4회의 중량부하 강제수영을 실시하였다.Male ICR mice at 5 weeks of age were supplied from Korea BiLink (Korea). Animals were fed with solid feed (no antibiotics, Samyang Feed Co.) and water until the day of experiment, 55 ± 15%, 12 hour light-dark cycle, and adapted for 1 week. In order to induce stress and fatigue, 5% of body weight was attached to the tail of a mouse, and a total of 4 times of weight load forced swimming was performed once a day for 30 minutes before the test day.
4. 추출물의 투여4. Administration of the extract
모든 추출물은 0.5% CMC가 함유된 생리식염수를 용매(vehicle)로 사용하여 농도별로 제조한 후, 투여 전까지 -20℃에서 보관하였으며 투여 직전 녹여서 사용하였다. All of the extracts were prepared by using physiological saline containing 0.5% CMC as a vehicle, and stored at -20 ° C. until administration, and were dissolved just before administration.
경구 투여는 10일 동안 실험동물이 운동을 시작하기 1시간 전에 실시하였다. 대조군(vehicle)은 0.5% CMC가 함유된 0.1㎖의 생리식염수를 투여하였고, 잣나무 잎 추출물 투여군(PKE-100, PKE-200)은 100mg/kg 및 200mg/kg의 잣나무 잎 추출물을 0.1㎖씩 투여하였다. 양성대조군(PC)은 100mg/kg의 홍경천 추출물(Rhodiola rosea extract)을 0.1 ㎖씩 투여하였다. Oral administration was carried out 10 days before the start of the exercise. The control group was administered 0.1 ml of physiological saline containing 0.5% CMC, and the pine needle leaf extract administration group (PKE-100, PKE-200) administered 100 mg / kg and 200 mg / kg pine needle leaf extract Respectively. The positive control (PC) was administered with 0.1 ㎖ of 100 mg / kg Rhodiola rosea extract.
5. 체중 측정5. Weight measurement
ICR 생쥐의 체중을 1, 5, 10일째 일정한 시간에 측정하였으며, 측정은 실험동물 사육실 내 정밀저울로 측정하였다. The body weights of ICR mice were measured at 1, 5, and 10 days at constant time, and measurements were made with precision scales in the experimental animal room.
6. 스트레스 부가 강제수영검사(Weight-Loaded Forced Swimming Test)6. Weight-Loaded Forced Swimming Test
스트레스 부가 강제수영검사를 위해 투명 아크릴로 제작된 원통의 수조(Visionscientific Co., Korea)에 ICR 생쥐의 꼬리가 바닥에 닿지 않을 정도 깊이의 물을 넣고 25±1℃의 수온을 유지시켰다. 수영 지속시간은 10일째 투여가 끝난 후, 1시간 후에 ICR 생쥐 꼬리에 체중의 5%에 해당하는 무게 추를 부착하고 video tracking software (SMART 3.0, Panlab, Spain)를 이용하여 생쥐의 코가 수면 아래로 5초 이상 가라앉을 시점을 측정하여 평가하였다. The water of the ICR mice was immersed in water to a depth of 25 ± 1 ° C so that the tail of the ICR mice did not touch the bottom of the cylindrical water tank (Visionscientific Co., Korea) made of transparent acrylic for the forced swimming test. The duration of swimming was 10 minutes after the end of the administration, 1 hour after attaching weight to the ICR mouse tail by 5% of the weight and using video tracking software (SMART 3.0, Panlab, Spain) And the time of sinking for 5 seconds or longer was measured and evaluated.
7. 혈장 내 생화학적 성분 분석7. Analysis of biochemical components in plasma
생화학 성분분석을 위한 혈액시료는 실험시작 11일째에 30분간 중량부하 없이 강제수영을 실시한 후, 채취하였다. 젖산(Lactate)은 채취된 혈액으로 Lactate Pro2(Arkray, Japan)를 이용하여 젖산 산화효소 전극 방법으로 측정하였다. 암모니아(Ammonia), 혈액요소질소(Blood urea nitrogen, BUN), 젖산탈수화효소(Lactate dehydrogenase, LDH)는 채취된 혈액을 heparine이 함유된 tube에 넣고 항응고 처리한 후 1,000xg로 10분간 원심분리하여 혈장을 분리하고, 혈액분석기(Fuji Dri-Chem 7000i, Japan)를 이용하여 colorimetry 방법으로 측정하였다. Blood samples for biochemical analysis were collected by forced swimming without weight load for 30 minutes on the 11th day of the experiment. Lactate was measured by lactic acid oxidase electrode method using Lactate Pro2 (Arkray, Japan) as the collected blood. Ammonia, blood urea nitrogen (BUN) and lactate dehydrogenase (LDH) were collected by centrifugation at 1,000 × g for 10 min in an anticoagulant tube containing heparine Plasma was isolated and measured by colorimetry using a blood analyzer (Fuji Dri-Chem 7000i, Japan).
8. 혈장 내 8. Plasma 코르티졸Cortisol (( CortisolCortisol ) 함량 측정) Content measurement
실험동물로부터 분리한 혈장에서 코르티졸 함량을 측정하였다. 코르티졸은 경쟁적 효소 면역측정법으로 코르티졸 ELISA Kit(Cayman Chemical Company, Ann Arbor, MI, USA)를 이용하여 측정하였다. 50㎕의 표준물질과 시료(혈장)에, 코르티졸 AChE tracer 및 ELISA 모노클로날 항체를 첨가하였다. 이후, 4℃에서 밤새도록 반응한 후 세척과정을 거친 후, Ellman's 시약을 넣어 2시간 동안 반응시킨 후 405 nm의 파장에서 흡광도를 측정하였다.Cortisol content was measured in plasma separated from experimental animals. Cortisol was measured by a competitive enzyme immunoassay using the Cortisol ELISA Kit (Cayman Chemical Company, Ann Arbor, MI, USA). Cortisol AChE tracer and ELISA monoclonal antibodies were added to 50 μl of standard material and sample (plasma). Thereafter, the reaction was carried out overnight at 4 ° C., followed by washing. Ellman's reagent was added thereto for 2 hours, and the absorbance at 405 nm was measured.
9. 통계처리9. Statistical processing
모든 데이터는 평균±표준편차(mean±SD)로 표시하였다. 각 실험군의 결과값은 통계프로그램(one-way ANOVA : Tukey’s multiple comparison test)을 사용하여 통계처리 하였으며, p<0.05 이하의 수준에서 유의성 검정을 실시하였다(#: p<0.05, ##: p<0.01, ###: p<0.001, ####: p<0.0001 vs. vehicle). All data were expressed as mean ± SD (mean ± SD). The results of each experimental group were statistically analyzed using one-way ANOVA (Tukey's multiple comparison test), and a significance test was performed at a level of p <0.05 or less (#: p <0.05, ##: p < 0.01, ###: p <0.001, ####: p <0.0001 vs. vehicle).
실시예Example 1. 잣나무 잎 추출물의 스트레스 및 피로개선 효과 1. Stress and fatigue improvement effect of Pine leaf extract
본 실시예 1에서는 상기 실험방법에 따라 잣나무 잎 추출물의 투여에 따른 스트레스 및 피로개선 효과를 확인하였다. 상세하게는 상기 실험방법에 따라, 스트레스 및 피로를 유발하기 위하여 10일 동안 ICR 생쥐에 대조군(Vehicle)에는 5% CMC가 함유된 생리 식염수를 투여하였으며, 잣나무 잎 추출물 투여군(PKE)에서는 잣나무 잎 추출물 100mg/kg(PKE-100), 200mg/kg(PKE-200)을 투여하였다. 양성 대조군(PC)에는 100mg/kg의 홍경천 추출물을 투여하였다. 그 후 1시간 후에, 생쥐 체중의 5%에 해당하는 무게 추를 생쥐 꼬리에 부착하고 시험일 전까지 격일로 1회 30분간, 총 4회의 강제수영을 실시하여 스트레스 및 피로를 유발하였다. 10일째 투여가 끝난 후, 1시간 후에, ICR 생쥐 꼬리에 체중 5%의 무게를 부가하고 중량부하 강제수영검사를 실시하여 수영지속시간을 측정하였으며, 실험이 끝난 후 체중변화를 관찰하고 스트레스 및 피로관련 생리적 표적물질을 검사하였다. In Example 1, the stress and fatigue-improving effect of the extract of P. fomulus leaf was confirmed by the above-mentioned experimental method. In detail, according to the above experimental method, physiological saline containing 5% CMC was administered to the ICR mice for 10 days to induce stress and fatigue. In the PKE group, 100 mg / kg (PKE-100) and 200 mg / kg (PKE-200). The positive control (PC) was administered with 100 mg / kg of Hongkryung Stream extract. One hour later, a weight corresponding to 5% of the mice 'weight was attached to the tail of the mice, and the animals were subjected to forced swimming for a total of 4 times for 30 minutes every day until the test day to induce stress and fatigue. One hour after the administration on the 10th day, the weight of 5% of ICR mice was added to the tail of the ICR, and the swimming duration was measured by the weight load forced swimming test. The weight change was observed after the experiment, Related physiological target substances were examined.
1) 체중 변화 확인1) Confirm weight change
잣나무 잎 추출물이 스트레스 및 피로가 유발된 ICR 생쥐의 체중에 미치는 영향을 확인하였다. Effects of pine needle leaf extract on body weight of stressed and fatigued ICR mice.
그 결과 도 1에 개시한 바와 같이, 전체적으로 5일째 체중이 감소하였으나, 10일째에는 잣나무 잎 추출물 투여군(PKE-100, PKE-200)의 체중이 음성 대조군(Vehicle) 및 양성대조군(PC)과 유의적인 차이를 보이면서 체중을 회복하는 것을 확인하였다. As a result, as shown in Fig. 1, the body weight decreased on the 5th day as a whole. On the 10th day, the body weight of the pine needle leaf extract administration group (PKE-100, PKE-200) And it was confirmed that the body weight was restored.
2) 수영지속 시간에 미치는 효과2) Effect on swimming duration
중량부하 강제수영검사는 피로개선 효과를 확인하기 위해 널리 사용되고 있는 검사이다. 수영운동 시 물에 들어가면, 체온이 저하되고 열 생산이 증가함으로써 많은 열량이 소비되며, 근육운동의 대부분이 골격근에서 이루어지게 되어 스트레스 및 피로를 유발하여 운동지속 능력이 감소하게 된다. Weight load forced swimming test is a widely used test to confirm fatigue improvement effect. When you go into the water during swimming, the body temperature is lowered and the heat production is increased, so a lot of heat is consumed, and most of the muscle movements are made in the skeletal muscle, which causes stress and fatigue and decreases the exercise capacity.
스트레스 및 피로가 유발된 ICR 생쥐에서의 잣나무 잎 추출물이 수영지속시간(Swimming time)에 미치는 영향을 확인하기 위하여 중량부하 강제수영검사를 수행하였다. To investigate the effects of pine tree leaf extract on stress and fatigue induced swimming time in ICR mice, weight load forced swimming test was performed.
그 결과 도 2에 나타난 바와 같이, 100mg/kg의 잣나무 잎 추출물 투여군 및 양성대조군(PC)이 음성 대조군(Vehicle)에 비하여 수영지속 시간이 유의적으로 증가한 것을 확인하였다. As a result, as shown in FIG. 2, the swimming duration of 100 mg / kg of pine needle leaf extract-treated group and the positive control group (PC) was significantly increased compared to the negative control group.
3) 젖산 함량에 미치는 효과3) Effect on lactic acid content
고강도 운동 시 산소 공급량이 근육의 산소 소모량에 미치지 못하는 경우 근육 조직의 젖산 농도는 증가하게 되고, 이때 생성된 젖산은 혈액으로 확산되어 심장 및 간에서 처리하게 되어 체내 산성화가 초래하게 되며 피로를 유발시킨다. If the oxygen supply during the high intensity exercise is less than the oxygen consumption of the muscles, the lactic acid concentration in the muscle tissue is increased, and the lactic acid produced is diffused into the blood to be treated in the heart and liver, resulting in internal body acidification and fatigue .
따라서 본 발명의 유효성분인 잣나무 잎 추출물이 스트레스 및 피로가 유발된 ICR 생쥐의 혈액 내에 축적된 젖산(lactate)의 함량에 미치는 영향을 확인하고자 하였다. 상세하게는 상기 실험방법에 따라, 스트레스 및 피로가 유발된 ICR 생쥐의 혈액을 Lactate Pro2(Arkray, Japan)를 이용하여 젖산 산화효소 전극 방법으로 젖산의 함량을 측정하였다.Therefore, the effect of the extract of P. intestinalis, an active ingredient of the present invention, on the content of lactate accumulated in the blood of stressed and fatigued ICR mice was examined. Specifically, the blood of ICR mice induced by stress and fatigue was measured by lactic acid oxidase electrode method using Lactate Pro2 (Arkray, Japan) according to the above experimental method.
그 결과 도 3에 개시한 바와 같이, 잣나무 잎 추출물 투여군(PKE-100, PKE-200)이 음성 대조군(Vehicle)에 비하여 젖산의 양이 유의적으로 감소하는 것으로 나타났다. As a result, as shown in FIG. 3, the amount of lactic acid was significantly decreased in the group treated with the extract of Pinus koraiensis (PKE-100, PKE-200) compared to the negative control group.
4) 암모니아 함량에 미치는 효과4) Effect on Ammonia Content
아스파르트산은 근육 내에서 퓨린 뉴클레오티드(purine nucleotide) 회로의 주요 구성분으로, 심한 고강도 운동 중에 ATP 풀을 재생시켜 근육에 에너지를 제공하고, 이 과정에서 유리 암모니아를 형성한다. 운동의 강도 또는 시간에 따라 아미노산의 분해 결과 생성된 암모니아는 근육으로부터 혈액으로 방출되고, 혈중 암모니아는 뇌에 전달되어 중추 피로를 증가시킨다. 한편 근육세포에 축적된 암모니아는 근육의 통증 감지와 관련이 있는 구심성 신경을 자극하고, TCA 회로 및 당 신생 작용을 저해하며, 젖산 생성을 초래함으로써 근육의 피로를 유발시킨다.Aspartic acid is a major component of the purine nucleotide circuit in the muscle, regenerating the ATP pool during intense high-intensity exercise, providing energy to the muscle and forming free ammonia in the process. Depending on the strength or time of exercise, the ammonia produced as a result of the degradation of amino acids is released from the muscle into the blood, and the blood ammonia is transferred to the brain to increase the central fatigue. On the other hand, the accumulation of ammonia in muscle cells stimulates the afferent nerves that are associated with muscle pain sensation, inhibits the TCA cycle and glycogenesis, and causes muscle fatigue by causing lactic acid production.
이에 본 발명의 잣나무 잎 추출물이 피로가 유발된 ICR 생쥐의 혈액 내에서 암모니아(ammonia) 함량에 미치는 영향을 확인하였다. 상세하게는 상기 실험방법에 따라, 스트레스 및 피로가 유발된 ICR 생쥐의 혈액을 회수하여 원심분리한 후 혈청 부분을 혈액분석기(Fuji Dri-Chem 7000i, Japan)를 이용하여 colorimetry 방법으로 암모니아 함량을 측정하였다.Thus, the effect of the extract of P. vannamei on the ammonia content in blood of ICR mice induced by fatigue was examined. Specifically, the blood of ICR mice induced by stress and fatigue was recovered and centrifuged according to the above-mentioned experimental method. The serum portion was measured by a colorimetry method using a blood analyzer (Fuji Dri-Chem 7000i, Japan) to measure the ammonia content Respectively.
그 결과 도 4에 개시한 바와 같이, 잣나무 잎 추출물 투여군(PKE-100, PKE-200)이 음성 대조군(Vehicle)에 비하여 암모니아 농도가 유의적으로 감소하는 것으로 나타났다. As a result, as shown in Fig. 4, the ammonia concentration was significantly decreased in the pine needle leaf extract administration group (PKE-100, PKE-200) as compared with the negative control group (Vehicle).
5) 5) 혈액요소질소Blood element nitrogen 함량에 미치는 효과 Effect on content
요소질소는 체내 단백질대사의 최종산물이며, 강렬한 운동 후에 당류나 지방 이화작용에 의한 에너지 공급이 부족한 상태에서 단백질과 아미노산 이화작용이 일어나고 요소질소가 증가한다. 그러므로 혈액요소질소의 증가를 통해서 단백질이나 아미노산의 이화작용 및 피로가 유발되었음을 알 수 있다.Urea is the final product of protein metabolism in the body. After intense exercise, protein and amino acid catabolism occurs and urea nitrogen is increased in the state of insufficient supply of energy by saccharide or lipidation. Therefore, it can be seen that the increase of blood urea nitrogen induced the catabolism and fatigue of protein or amino acid.
잣나무 잎 추출물이 스트레스 및 피로가 유발된 ICR 생쥐의 혈액 내에서 혈액요소질소(Blood urea nitrogen, BUN) 함량에 미치는 영향을 확인하였다. 상세하게는 상기 실험방법에 따라, 스트레스 및 피로가 유발된 ICR 생쥐의 혈액을 회수하여 원심분리한 후 혈청 부분을 혈액분석기(Fuji Dri-Chem 7000i, Japan)를 이용하여 colorimetry 방법으로 혈액요소질소 함량을 측정하였다.The effects of Pine needle leaf extract on the blood urea nitrogen (BUN) content in the blood of stressed and fatigued ICR mice were examined. Specifically, the blood of ICR mice induced by stress and fatigue was collected and centrifuged, and the serum portion was analyzed by colorimetry using a blood analyzer (Fuji Dri-Chem 7000i, Japan) to determine the blood urea nitrogen content Were measured.
그 결과 도 5에 개시한 바와 같이, 잣나무 잎 추출물 투여군(PKE-100, PKE-200)이 음성 대조군(Vehicle)에 비하여 혈액요소질소(BUN)의 농도가 유의적으로 감소하는 것으로 나타났다. As a result, as shown in FIG. 5, the concentration of blood urea nitrogen (BUN) in the pine needle leaf extract administration group (PKE-100, PKE-200) was significantly lower than that of the negative control group.
6) 6) 젖산탈수화효소Lactate dehydrogenase 함량에 미치는 효과 Effect on content
젖산탈수화효소는 근활동 중 근세포에서의 젖산 생성과 전환을 조절하는 역할을 하며, 운동 후 활성이 증가하고, 혈중 젖산탈수화효소의 활성 증가는 세포 손상의 지표가 된다.Lactate dehydrogenase plays a role in regulating the production and conversion of lactic acid in muscle cells during muscle activity, increasing post - exercise activity, and increasing the activity of lactate dehydrogenase in blood is an indicator of cell damage.
잣나무 잎 추출물이 스트레스 및 피로가 유발된 ICR 생쥐의 혈액 내에서 젖산탈수화효소(Lactate dehydrogenase, LDH) 함량에 미치는 영향을 확인하였다. 상세하게는 상기 실험방법에 따라, 스트레스 및 피로가 유발된 ICR 생쥐의 혈액을 회수하여 원심분리한 후 혈청 부분을 혈액분석기(Fuji Dri-Chem 7000i, Japan)를 이용하여 colorimetry 방법으로 젖산탈수화효소 함량을 측정하였다.Effects of Pinus koraiensis L. extract on the lactate dehydrogenase (LDH) content in the blood of stressed and fatigued ICR mice. Specifically, the blood of ICR mice induced by stress and fatigue was collected and centrifuged, and the serum portion was analyzed by colorimetry using a blood analyzer (Fuji Dri-Chem 7000i, Japan) And the content thereof was measured.
그 결과 도 6에 개시한 바와 같이, 잣나무 잎 추출물 투여군(PKE-100, PKE-200)이 음성 대조군(Vehicle)에 비하여 젖산탈수화효소(LDH)의 농도가 유의적으로 감소하는 것으로 나타났다. As shown in FIG. 6, the concentration of lactate dehydrogenase (LDH) was significantly decreased in the pine needle leaf extract-treated group (PKE-100, PKE-200) compared to the negative control group.
7) 7) 코르티졸Cortisol 함량에 미치는 효과 Effect on content
코르티졸은 부신피질에서 분비되는 스테로이드 호르몬으로 스트레스원에 대한 개체의 반응과 항상성의 조절에 관여한다. 코르티졸은 정신적인 스트레스를 받았을 때 상대적으로 농도가 증가하며 혈압 및 맥박을 증가시킨다. 코르티졸의 농도가 높을수록 스트레스가 높음을 의미한다. Cortisol is a steroid hormone secreted from the adrenal cortex and is involved in the regulation of the response and homeostasis of individuals to stressors. Cortisol increases micturition stress and increases blood pressure and pulse rate. The higher the concentration of cortisol, the higher the stress.
잣나무 잎 추출물이 스트레스 및 피로가 유발된 ICR 생쥐의 혈액 내에서 코르티졸(Cortisol) 함량에 미치는 영향을 확인하였다. 상세하게는 상기 실험방법에 따라, 스트레스 및 피로가 유발된 ICR 생쥐의 혈액을 회수하여 원심분리한 후 혈청 부분을 코르티졸 ELISA Kit(Cayman Chemical Company, Ann Arbor, MI, USA)를 이용하여 효소면역 측정법으로 코르티졸의 함량을 측정하였다.The effect of Pine needle leaf extract on the Cortisol content in the blood of stressed and fatigued ICR mice was examined. Specifically, the blood of the ICR mice induced by stress and fatigue was collected and centrifuged, and the serum portion was analyzed by enzyme immunoassay using a Cortisol ELISA Kit (Cayman Chemical Company, Ann Arbor, MI, USA) And the content of cortisol was measured.
그 결과 도 7에 개시한 바와 같이, 잣나무 잎 추출물 투여군(PKE-100, PKE-200)이 음성 대조군(Vehicle)에 비하여 코르티졸의 농도가 유의적으로 감소하는 것으로 나타났다. As a result, as shown in FIG. 7, the concentration of cortisol was significantly decreased in the pine needle leaf extract-administered group (PKE-100, PKE-200) compared to the negative control group.
Claims (6)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170168909A KR102021280B1 (en) | 2017-12-11 | 2017-12-11 | Composition for fatigue recovery comprising Pinus koraiensis leaves extract as effective component |
PCT/KR2018/015632 WO2019117568A1 (en) | 2017-12-11 | 2018-12-10 | Composition for fatigue recovery containing pinus koraiensis leaf extract as active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170168909A KR102021280B1 (en) | 2017-12-11 | 2017-12-11 | Composition for fatigue recovery comprising Pinus koraiensis leaves extract as effective component |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190085565A true KR20190085565A (en) | 2019-07-19 |
KR102021280B1 KR102021280B1 (en) | 2019-09-16 |
Family
ID=66820751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170168909A KR102021280B1 (en) | 2017-12-11 | 2017-12-11 | Composition for fatigue recovery comprising Pinus koraiensis leaves extract as effective component |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102021280B1 (en) |
WO (1) | WO2019117568A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005097273A (en) * | 2003-08-19 | 2005-04-14 | Toyo Shinyaku:Kk | Athletic ability-enhancing composition |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030062189A (en) * | 2002-01-16 | 2003-07-23 | 김도영 | pine-nuts tree containing rice manufacturing method. |
KR101260778B1 (en) * | 2010-08-02 | 2013-05-06 | 이영환 | Beverage containing extracts from pine-nuts tree |
-
2017
- 2017-12-11 KR KR1020170168909A patent/KR102021280B1/en active IP Right Grant
-
2018
- 2018-12-10 WO PCT/KR2018/015632 patent/WO2019117568A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005097273A (en) * | 2003-08-19 | 2005-04-14 | Toyo Shinyaku:Kk | Athletic ability-enhancing composition |
Non-Patent Citations (2)
Title |
---|
겨울철 감기 예방하는 차ㆍ음료, 식품산업경제뉴스, (2012.11.28.) 1부.* * |
잣잎(백엽)을 이용한 기능성식품 소재 탐색 및 상품화, 최종연구보고서, 농림수산식품부, (2010.05.27.) 1부.* * |
Also Published As
Publication number | Publication date |
---|---|
WO2019117568A1 (en) | 2019-06-20 |
KR102021280B1 (en) | 2019-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11382943B2 (en) | Medicinal composition of amaranth extract origin having enriched nitrate content and a method of preparing the same | |
US20130261136A1 (en) | Coffee extracts as ingredients of foods, drugs, cosmetics, dietary supplements, and biologics | |
KR20160017223A (en) | Composition for muscle development and muscle fatigue recovery comprising Angelica keiskei extract and Red ginseng extract as active ingradients | |
CN106456693A (en) | Agent for preventing or ameliorating diabetes | |
JP2008237117A (en) | Anti-fatigue food raw material and anti-fatigue food | |
JP6446162B1 (en) | Hangover composition | |
CN105722520A (en) | Sugar cane derived extracts and methods of treatment | |
JP2013075874A (en) | Blood sugar metabolism improver | |
KR101076535B1 (en) | Food composition for relieving hangover which comprises extract of lithospermum erythrorhizon as an active component | |
KR101689259B1 (en) | Composition having effects of preventing or recovering fatigue or stress | |
KR100526631B1 (en) | Composition comprising the extract of Morus alba L having monoamine oxidase-inhibiting activity | |
KR102021280B1 (en) | Composition for fatigue recovery comprising Pinus koraiensis leaves extract as effective component | |
KR100727396B1 (en) | Composition comprising extract of Citrullus vulgaris bark and octacosanol | |
KR100496524B1 (en) | Composition for eliminating hangover | |
KR20110002392A (en) | Sports beverage composition comprising salicornia herbacia extacts | |
KR20000026785A (en) | Herb medicine-containing accelerant for alcohol metabolism | |
KR100526628B1 (en) | Composition comprising the extract of Morus alba L having monoamine oxidase-inhibiting activity | |
KR101157096B1 (en) | Composition for relieving hangover containing Bulnesia sarmienti extracts | |
CN105380267B (en) | A kind of functional food and preparation method thereof | |
RU2765133C1 (en) | Tea composition | |
KR102395338B1 (en) | Oral composition for improving systemic symptoms including sensitivity to cold | |
JPWO2007004570A1 (en) | Composition having improved endurance and / or anti-fatigue action | |
KR20170122612A (en) | Composition and its manufacturing method for sports nutrition comprising of Trigonella foenum-graecum extract and ferulic acid | |
JP2015113309A (en) | Composition containing natural extract | |
KR20170055368A (en) | A composition for alleviating or treating symptoms caused by liver function decreases comprising taraxacum coreanum root extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |